Kiran Mazumdar

According to the GLOBOCAN 2020 report, India witnesses over 2.25 lakh new head and neck cancer cases every year out of which over 1.25 lakh deaths are reported every year

Indian pharma must ensure compliance with global standards: Kiran Mazumdar-Shaw

Slowing global economic conditions are expected to trigger greater utilisation of generic drugs and biosimilars because they offer lower-cost alternatives to expensive branded drugs, she said.

Biocon aims to become the largest biosimilar company globally: Kiran Mazumdar-Shaw

Biocon Chairman sees biologics business hitting Rs 2,000 crore in the fourth quarter; says there's a need to build robust regulatory system to curb instances of adulteration of drugs by Indian pharma firms.

Exclusive | Pharma manufacturing needs a robust regulatory system: Kiran Mazumdar-Shaw

Shaw appreciated the Indian pharma sector’s commitment to ethical manufacturing practices but highlighted the need for credibility and quality control.

Biocon chief bats for easing regulations on biotech sector

"The erstwhile UPA regime and the present Modi government have taken some good steps, but have not done enough to improve the economy," Shaw told PTI in an interview after the inauguration of Bengaluru Tech Summit 2018.

The Growth Net Summit: Discussing the reform agenda

At the Growth Net 5th Annual India Summit, Shereen Bhan got together with Prakash Javdekar, HRD Minister, Kiran Mazumdar Shaw of Biocon, Uday Kotak of Kotak Mahindra Bank, Henny Sender of The Financial Times and Nicholas Stern, professor at LSE to discuss the reform agenda in India.

Narayana Hrudayalaya IPO opens: Expensive but subscribe

ICICIdirect.com advises to subscribe stating though it thinks valuation is a tad expensive, it is in line with the recent deals in the healthcare industry. It says that Narayana's calibrated model for establishing and expanding its hospitals has allowed it to achieve a more efficient use of capital than many of its peers.

Battle for rights continue as IIM-A hits out at HRD

The fight between the HRD ministry and India's premier management institutes does not seem to cease as IIM Ahmedabad words its letter in opposition.

India Inc to policymakers: shape up, or we'll ship out

Many top entrepreneurs have voiced frustration that policymakers failed to keep economic reforms rolling over the past decade, which they contend would have prevented India from stumbling into its deepest economic crisis since 1991.

Biocon expects oral insulin partner by March

Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday.

Clinigene & Syngene may list in a year's time: Biocon

In an exclusive interview with CNBC-TV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene & Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 24-36 months.